Hello my dears,
I have just invested and am sticking with it.
Lund, Sweden - August 28, 2025 - Camurus (NASDAQ STO: CAMX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Oczyesa ®, a subcutaneous octreotide depot, for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.1
" Oczyesa, the first subcutaneous octreotide treatment for monthly administration, has demonstrated effective and sustained control of acromegaly and can be self-administered by patients using an auto-injection pen, " says Fredrik Tiberg, President & CEO, CSO at Camurus. " Camurus plans to launch the treatment in the UK in the fourth quarter of 2025. "
The MHRA's marketing authorization of Oczyesa is based on the results of a comprehensive clinical program comprising seven clinical trials, including two Phase 3 trials under the ACROINNOVA program.
Oczyesa is manufactured using Camurus' proprietary FluidCrystal® technology. The product is designed for convenient subcutaneous self-administration once monthly using a pre-filled autoinjector pen with a concealed thin needle.
Oczyesa received marketing authorization in the EU from the European Commission on June 30, 2025.
Information about acromegaly can be found at the link ⬇️
